New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer

Advanced Nasopharyngeal Carcinoma Clinical Trial

Official title:
Prospective Evaluation of Plasma EBV DNA Half-life and PET-CT Scanning as a New Tool in Assessing Early Response to Chemotherapy in Patients With Advanced Nasopharyngeal Carcinoma

Status Completed

Clinical Trial Summary

The combination of pEBV DNA (half-life) and PET-CT following 1 course of chemotherapy allow earlier and more detection of drug response in advanced NPC than RECIST method, in patients with previously untreated advanced NPC who will receive platinum-based chemotherapy. This study will also determine if this new method can predict survival in these patients. This study may have far-reaching impact on drug development in NPC as it may offer a more optimal way of evaluating drug efficacy in clinical trials and also in clinical management.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Nasopharyngeal Carcinoma
Carcinoma
Nasopharyngeal Neoplasms

Clinical Trial Details

NCT number	NCT01365208
Study type	Observational
Source	Chinese University of Hong Kong
Contact
Status	Completed
Phase	N/A
Start date	July 2011
Completion date	March 3, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05652192` - SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC	Phase 2
Recruiting	`NCT05751486` - A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma	Phase 1
Not yet recruiting	`NCT03723343` - GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma